丁丙诺啡舌下含片用于中、重度癌症镇痛的扩大临床验证

EXPANDING TRAIL OF BUPRENORPHINE HYDRACHLORIDE SUBLINGUAL TABLET ON THE MANAGEMENT OF MODERATE AND HEAVY CANCER PAIN

目的 :进一步验证丁丙诺啡舌下含片用于中、重度癌痛患者的镇痛效果和不良反应 ,探索达到明显或完全疼痛缓解的用药剂量 ,以便更好地指导临床用药。方法 :采用多中心无对照开放试验。应用滴定法 ,调整日剂量 ,寻找 2 4h使癌痛患者无痛的给药剂量。结果 :中、重度癌症患者舌下含服丁丙诺啡 0 6 - 2 4mg·d- 1 的剂量 ,给药次数3- 4次 ,可明显或完全缓解疼痛。主要不良反应有头晕、思睡和恶心等。结论 :丁丙诺啡是一种镇痛效果较强 ,不良反应较轻 ,适用于中、重度疼痛的镇痛药 ,可用于癌痛患者第Ⅲ阶梯镇痛。

Objective: To further validate th e analgesic efficacy and adverse drug reactions of buprenorphine sublingual tablet s for the management of moderate and heavy cancer pain and find out the a dequate dose for complete or obvious pain relief so as to establish a rational a dminist ration in clinical practice. Methods: An open clinical trial was conducted to confirm daily dose according to adjustment by dose titration. Results: Pain could be controlled completely or obviously by administering buprenorphine 0.6-2.4 mg·d -1, three to four times a day. The adverse reactions such as dizziness,drowsiness and vomiting were observed. Conclusion: Buprenorphine sublingual tablets are strong anal gesics with slight side effects, which can be used by cancer patients for contr olling moderate and heavy pain.